Cegardex®

Prevention of:

precancerous genital lesions (cervical intraepithelial neoplasia grade ½/3 (CIN), adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN) grade ½/3, and precancerous anal lesions — anal intraepithelial neoplasia (AIN) grade ½/3), caused by human papillomavirus (HPV) types 6, 11, 16, and 18;
cervical, vulvar, vaginal and anal cancers caused by HPV types 16 and 18;
anogenital warts (condyloma acuminata) caused by HPV types 6 and 11.¹

For males and females aged 18 to 45 years.¹

1. Belaya Yu.M., Zarochentseva N.V., Lopukhov P.D. HPV Vaccination: Regional Experience of the Moscow Region. Issues of Practical Colposcopy. Genital Infections. 2025; 2: 6–9. DOI: 10.46393/2782_6392_2025_2_6–9.
2. Belotserkovtseva L.D., Mayer Yu.I., Konareva I.G. Cervical Screening Results in Women Vaccinated Against HPV in Adolescence Under the Regional HPV Immunization Program in KhMAO–Yugra. Reproductive Health of Children and Adolescents. 2025; 21(3): 5–16. DOI: https://doi.org/10.33029/1816-2134-2025-21-3-5-16.
3. Gomberg M.A., Kim D.G. Anogenital Warts: From Epidemiological Recording Challenges to the Proven Impact of HPV Vaccination on Population Health as a Marker of Global Success in Combating HPV. Clinical Dermatology and Venereology. 2025; 24(4): 504–510. https://doi.org/10.17116/klinderma202524041504.

The recommended vaccination course consists of 3 doses administered according to the 0–2–6 month schedule: